Hang Chen

Hang Chen is a serial entrepreneur who has co-founded and led two distinct AI companies in different sectors. He was co-founder and CEO of Neox Biotech (星亢原), a drug-discovery startup founded in 2018 that applied AI, biophysics, and high-throughput experimentation to design biologic drugs and PROTAC degraders — described in a 2022 5Y Capital piece as China's first company to focus on AI-driven macromolecular drug development . More recently, he has emerged as co-founder and CEO of Manycore Tech (群核科技), a spatial-intelligence company that filed for a Hong Kong IPO in early 2026 and positions itself as a "pick-and-shovel" infrastructure provider for the 3D AI era . The shift from biotech to spatial computing marks a notable pivot in his career trajectory, with Yunqi Capital covering his overseas expansion strategy for Manycore in mid-2025 .